QR-1123
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for QR-1123, covering 2022-05-06 to 2022-05-06. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene [Phase 1, Phase 2]